Janssen's Lebowitz On J&J's Oncology Expansion Plans Outside Of Hematology
Janssen global oncology therapeutic area head Peter Lebowitz talked to Scrip about the company's next big ambitions in lung, bladder and prostate cancer.
You may also be interested in...
Improvements in PFS compared to chemotherapy may help broaden Rybrevant’s indication in EGFR-mutated non-small cell lunger cancer. Investors await data from a head-to-head trial testing it versus AstraZeneca’s Tagrisso.
A Phase III trial of Rybrevant with lazertinib versus Tagrisso in first line EGFR-positive NSCLC is continuing after an interim analysis, surprising some investors who thought it might be stopped early for efficacy.
With Darzalex and Carvykti already making J&J a leader in the field, the company has added another dimension to its offering with the first multiple myeloma bispecific antibody therapy.